초록 ▼

Novel preventive treatment for COVID 19 and therapeutic treatment for early stages of COVID 19 or any other disease caused by SARS CoV 2. Pharmaceutical formulations and devices are disclosed to be able to implement these treatments. These treatments to prevent and alleviate the symptoms at early st

Novel preventive treatment for COVID 19 and therapeutic treatment for early stages of COVID 19 or any other disease caused by SARS CoV 2. Pharmaceutical formulations and devices are disclosed to be able to implement these treatments. These treatments to prevent and alleviate the symptoms at early stages of COVID 19, the pandemic disease caused by SARS CoV 2. These treatments are based on the administration the nasal cavity and/or the lungs of solutions containing iota Carrageenan with or without the addition of xylitol as antiviral drug substances.

대표청구항 ▼

1. A nasal solution comprising a composition consisting of about 0.001% w/v to about 0.50% w/v iota carrageenan and about 0.5% w/v to about 5% w/v of xylitol as active agents, and one or more of osmolytes, buffers and combinations thereof, wherein the nasal solution is free of sugars or sugar alcoho

1. A nasal solution comprising a composition consisting of about 0.001% w/v to about 0.50% w/v iota carrageenan and about 0.5% w/v to about 5% w/v of xylitol as active agents, and one or more of osmolytes, buffers and combinations thereof, wherein the nasal solution is free of sugars or sugar alcohols, wherein xylitol is the only sugar alcohol present, and is hypotonic to slightly hypertonic having an osmolality of about 100-400 mOsm/kg. 2. The nasal solution of claim 1, wherein the osmolytes is sodium chloride. 3. The nasal solution of claim 1, wherein the buffers comprise at least one of: citric acid/sodium citrate, disodium hydrogen phosphate/sodium dihydrogen phosphate, acetic acid/sodium acetate or combinations thereof. 4. The nasal solution of claim 1, wherein the nasal spray is delivered by a preservative-free metering pump delivering from about 50 microliters up to 200 microliters (μl) of the solution per puff. 5. The nasal solution of claim 1, wherein the active agents are anti-viral agents. 6. The nasal solution of claim 5, wherein the anti-viral agents treat coronavirus infections. 7. The nasal solution of claim 6, the coronavirus is SARS CoV 2. 8. A pharmaceutical composition consisting of a therapeutically effective amount of 0.01% weight/volume (w/v) to about 0.50% w/v iota carrageenan, about 0.5% w/v to about 0.9% w/v sodium chloride, osmolytes, buffers and combinations thereof, wherein the iota carrageenan is an active agent and sorbitol is excluded. 9. The pharmaceutical composition of claim 8, wherein the buffers comprise: citric acid/sodium citrate, disodium hydrogen phosphate/sodium dihydrogen phosphate, acetic acid/sodium acetate or combinations thereof. 10. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is a nasal spray and is delivered by a preservative-free metering pump delivering from about 50 microliters (μL) up to 200 μL per puff. 11. A solution for nasal or lung nebulization consisting of about 0.01% w/v to about 0.50% w/v iota carrageenan, about 0.5% w/v to about 10% w/v xylitol and at least one buffer, wherein the at least one buffer comprises at least one of: citric acid/sodium citrate, disodium hydrogen phosphate/sodium dihydrogen phosphate, acetic acid/sodium acetate or combinations thereof, and wherein the solution is delivered by a preservative-free metering pump delivering about 50 microliters (μL) up to 200 μL per puff. 12. The solution of claim 11, wherein the solution is packaged into unit dose vials or any other suitable package for an unpreserved solution for nebulization. 13. A nasal solution comprising a composition consisting of about 0.001% w/v to about 0.50% w/v iota carrageenan and about 0.5% w/v to about 4% w/v of xylitol as active agents, and one or more of osmolytes, buffers and combinations thereof, wherein the nasal solution is free of sugars and is hypotonic having an osmolality of about 100-280 mOsm/kg. 14. A nasal solution comprising a composition consisting of about 0.001% w/v to about 0.50% w/v iota carrageenan and one or more of osmolytes, buffers and combinations thereof, wherein the nasal solution is free of sugars and is hypotonic having an osmolality of about 100-280 mOsm/kg.